Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting
Delcath Systems, Inc. (Nasdaq: DCTH) announced an upcoming Investor Update Meeting on December 2, 2021, focusing on its investigational drug/device combination product, HEPZATO KIT. The meeting will feature discussions on the FOCUS trial results and the clinical experience with CHEMOSAT, detailing unmet needs in treating liver cancers. A panel of leading physicians will present key topics including PHP quality of life and future clinical development plans. This event underscores Delcath's commitment to innovative solutions for liver cancer treatment.
- Detailed agenda for the Investor Update Meeting indicates a transparent approach to stakeholder engagement.
- Panel discussion featuring esteemed medical professionals highlights the credibility of Delcath's research and clinical data.
- HEPZATO KIT remains an investigational product in the U.S., which may indicate prolonged regulatory hurdles.
- Dependence on clinical trial results for future product development poses inherent risks.
Focus Trial Data and Future Development Plans to be Discussed by Management and KOLs
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd , from 10:00am ET – 1:30pm EST.
The event will focus on the company’s US product candidate, HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system), a percutaneous hepatic perfusion (PHP) system. In the United States HEPZATO is an investigational drug/device combination product. In Europe, the product is a stand-alone medical device approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
A distinguished panel of physicians will discuss their experience with HEPZATO in the FOCUS trial, commercial experience with CHEMOSAT and the unmet need in the treatment of liver metastases. The participating physicians will present on the following topics:
- Current unmet need and treatment options for liver metastases
- The longest single institution experience with PHP – The University Hospital Southampton experience
- PHP quality of life and combination with immuno-oncologic therapy – The Leiden University experience
- Current unmet needs in ocular melanoma
- Focus Trial – efficacy and safety results
- Future clinical development plans
In addition to the Delcath management team, planned speakers and panelists will include:
John Bridgewater, MRCP, PhD, FRCP
Professor and Consultant Medical Oncologist, UCL Cancer Institute, University College London, London, UK
Mark Burgmans, MD, PhD
Head of Interventional Radiology, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
Aslam Ejaz MD, MPH
Assistant Professor of Surgery, The Ohio State University, Columbus, OH
Francesco Pier Ferrucci, MD
Director, Tumor Biotherapy Unit, Istituto Europeo di Oncologia, Milan, Italy
Evan S. Glazer, MD, PhD, FACS
Assistant Professor of Surgery, College of Medicine and Principal Investigator, Center for Cancer Research, The University of Tennessee Health Science Center, Memphis, TN
Sachin Modi, BSc (Hons), MBBS, FRCR, FRCR (IR)
Consultant Interventional Radiologist, Department of Interventional Radiology, University Hospital Southampton, Southampton, UK
Siddharth A. Padia, MD
HS Clinical Professor, Division of Interventional Radiology, David Geffen School of Medicine, University of California, Los Angeles, CA
Sapna Patel, MD
Associate Professor, Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX
Sunil A. Reddy, MD
Clinical Assistant Professor, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California
Brian Stedman, BSc, MBBS, FRCS, FRCR
Consultant Interventional Oncologist, Department of Interventional Radiology, University Hospital Southampton, Southampton, UK
Juan Valle, MD
Professor and Consultant Medical Oncologist, The Christie NHS Foundation Trust, Manchester, UK
Jonathan Zager, MD, FACS (Global Lead Investigator)
Chief Academic Officer, Director of Regional Therapies, and Senior Member, Departments of Cutaneous Oncology and Sarcoma, Moffitt Cancer Center; Chair, Department of Oncological Sciences and Professor of Surgery, USF, Morsani School of Medicine, Tampa, FL
Event Details:
Event: Delcath Systems Virtual Investor Update Meeting
Date: Thursday, December 2, 2021
Time: 10:00am – 1:30 p.m. EST
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com
FAQ
What is the date of the Delcath Systems Investor Update Meeting?
What product will be discussed during the Delcath Systems event?
Who will be speaking at the Delcath Investor Update Meeting?
What trial results will be presented at the Delcath meeting?
What is the focus of Delcath Systems as a company?
